Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with rituximab may kill more cancer cells. It is not yet known whether giving combination chemotherapy together with rituximab is more effective than combination chemotherapy alone in treating chronic lymphocytic leukemia.

PURPOSE: This randomized phase II trial is studying how well giving combination chemotherapy with or without rituximab works in treating patients with previously treated chronic lymphocytic leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Research UK
• Treatments: Cyclophosphamide; Fludarabine; Fludarabine phosphate; Mitoxantrone; Rituximab

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of chronic lymphocytic leukemia requiring therapy

• Previously treated with ≥ 1 chemotherapeutic regimen

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

• Life expectancy ≥ 12 weeks

• Creatinine clearance ≥ 30 mL/min

• Not pregnant or nursing

• Negative pregnancy test

• Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment

• Fertile male patients must use effective contraception during and for 6 months after completion of study treatment

• No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies

• No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)

• No active infection

• No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride

• No prior rituximab, either alone or in combination with chemotherapy